Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (53)

I-022Jeff Barrett

Open-science solutions enabled within a digital research environment to support MIDD (Model Informed Drug Development) and precision dosing

Wednesday 10:20-11:50

I-041Divya Brundavanam

Addressing Confounding Bias in Exposure-Response Analysis: Evaluating Instrumental Variable Modeling Strategies

Wednesday 10:20-11:50

I-064Limei Cheng

Using machine learning to predict longitudinal platelet counts: a methodology framework

Wednesday 10:20-11:50

I-082Wilbert de Witte

In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models

Wednesday 10:20-11:50

I-085Abdallah Derbalah

Beyond the Liver; In Silico Screening for Tissue-Specific Oligonucleotide Delivery Receptors

Wednesday 10:20-11:50

I-097Jeroen Elassaiss-Schaap

Construction of IMPRES-M, a non-parametric impulse-response modeling method, in the context of varying pharmacokinetic profiles

Wednesday 10:20-11:50

I-102Ali Farnoud

A Neural Networks-assisted NLME Framework: Case Study on Modeling Platelet Counts

Wednesday 10:20-11:50

I-106Lucie FAYETTE

Using Fisher Information Matrix to predict covariate effects in forest plots and power of their relevance

Wednesday 10:20-11:50

I-109Matthew Fidler

nlmixr2, rxode2 and Monolix: interchangeable models using monolix2rx and babelmixr2

Wednesday 10:20-11:50

I-111Nuria Folguera-Blasco

Coupling Quantitative Systems Pharmacology (QSP) and ML/AI: a story of pAIns and gAIns

Wednesday 10:20-11:50

II-006Stefano Giampiccolo

Supporting pharmacometrics applications by robust parameter estimation and identifiability analysis using hybrid Neural ODEs

Wednesday 15:20-16:50

II-007Asina Gijasi

Structural model development with compartmental pharmacokinetic models for a range of small molecule subcutaneous data

Wednesday 15:20-16:50

II-013Sebastiaan Goulooze

The drug titration paradox in the presence of intra-individual variation: can we estimate the true concentration-effect relationship?

Wednesday 15:20-16:50

II-023Sofia Guzzetti

A modelling framework for in vitro/in vivo translation of PROTACs PK/PD and PK/Efficacy: accelerating drug discovery of targeted protein degraders

Wednesday 15:20-16:50

II-029Niklas Hartung

A unified Rodgers et al. model for predicting tissue partitioning reveals the need for a theoretical derivation of the Lukacova et al. (Simulations Plus) model

Wednesday 15:20-16:50

II-044Nathanaël Hozé

A multi-scale modelling framework to assess the relationship between SARS-CoV-2 viral load and transmission in household studies.

Wednesday 15:20-16:50

II-046Zhe Huang

Model-integrated bioequivalence method for highly variable drugs with long half-life: a simulation study comparing complete washout and incomplete washout designs

Wednesday 15:20-16:50

II-048Zhonghui Huang

Development and evaluation of nlmixr2auto: Automated open-source model building

Wednesday 15:20-16:50

II-056Ludvig Jakobsson

A frailty model for quantifying the association between CompEx risk and variation in lung function in asthma

Wednesday 15:20-16:50

II-058Alexander Janssen

Time-dependent random effects.

Wednesday 15:20-16:50

II-059Hyeseon Jeon

Comparative Study of Target Mediated Drug Disposition Approximation Methods Based on Validity Conditions: Application to Clinical Trial Studies

Wednesday 15:20-16:50

II-066Christos Kaikousidis

Quantification of model misspecification of population pharmacokinetic models by a machine learning postprocessing correction of the residual variability

Wednesday 15:20-16:50

II-092Alexandra Lavalley-Morelle

Extending the R open-source saemix package: a new tool for parametric joint models

Wednesday 15:20-16:50

II-093Jacob Leander

Simulation-based comparison of MMRM and dose-response MMRM for Ph2b dose-finding design in rheumatoid arthritis

Wednesday 15:20-16:50

II-098Cristina Leon

Enhancing statistical power in lipid-lowering therapy studies through optimization of the MACE endpoint composition: a model-based meta-analysis approach

Wednesday 15:20-16:50

II-105Andreas Lindauer

A Mini-Tutorial on Campsis: The R-Based PK/PD Simulation Suite

Wednesday 15:20-16:50

II-114Lorenzo Cifelli

ODE-free survival modeling with full pharmacokinetic profiles in the IMPRES-M framework

Wednesday 15:20-16:50

II-115Mark Lovern

Introducing InSilicoTrials NONMEM simulator: Cloud-based simulation tool for NONMEM models

Wednesday 15:20-16:50

III-002Moustafa M. A. Ibrahim

The reference corrected VPC – A more intuitive model diagnostic

Thursday 09:50-11:20

III-003Panos Macheras

Understanding the gastrointestinal absorption of drugs using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models: Focus on Biowaivers

Thursday 09:50-11:20

III-004Paolo Magni

Combining Reinforcement Learning and PK-PD models to personalize multiple drug administration: an application to Axitinib-Anti-Hypertensive treatment in metastatic renal cancer patients

Thursday 09:50-11:20

III-008Jialin Mao

Human PK prediction of Kras G12C covalent inhibitors: GDC-6036, AMG-510 and MRTX-849 using PBPK approach

Thursday 09:50-11:20

III-017Enrico Mastrostefano

Integrating PKPD and Agent-Based Modeling to Explore Tuberculosis Relapse after Treatment.

Thursday 09:50-11:20

III-081Elba Raimundez Alvarez

Evaluation of automated model development workflows for population pharmacokinetic models

Thursday 09:50-11:20

III-086Freek Relouw

Towards an Inflammation Simulation Model: Development and Validation of a Mathematical Model of the Human Inflammatory Response to Acute and Prolonged Lipopolysaccharide Exposure

Thursday 09:50-11:20

III-104Mark Sale

Performance of Machine Learning Algorithms for Model Selection

Thursday 09:50-11:20

III-106Sergio Sánchez Herrero

Individualized Prediction of Gentamicin Concentration in Neonates: A Multimodal Approach of PBPK Modeling and Machine Learning

Thursday 09:50-11:20

III-112Franziska Schädeli Stark

Performance evaluation of the Automatic Model Development (AMD) tool with real population pharmacokinetic datasets from clinical drug development projects

Thursday 09:50-11:20

IV-019Marie Steinacker

Combining biological knowledge and machine learning for predicting dynamics of haematotoxcity after chemotherapy: a comparative analysis

Thursday 15:00-16:30

IV-030Sebastian Tandar

Population-level treatment optimization using a multi-objective optimization strategy

Thursday 15:00-16:30

IV-035Donato Teutonico

Estimation of population parameter values and variability coupling non-linear mixed-effects modeling (based on SAEM algorithm) with a whole-body PBPK model

Thursday 15:00-16:30

IV-043Mirjam Trame

FOCE generalized log-likelihood using nlmixr2

Thursday 15:00-16:30

IV-044Van Thuy Truong

Stochastic pharmacodynamics: Drug effects on the time to extinction of a heterogeneous tumour cell population

Thursday 15:00-16:30

IV-058Martijn van Noort

User-friendly parameter identifiability methods with a workflow to guide model development, using categorical and continuous scales

Thursday 15:00-16:30

IV-067Esmée Vendel

Belimumab Pharmacokinetic Simulations to Select an Appropriate Subcutaneous Dosing Regimen to Treat Paediatric Patients with Active Lupus Nephritis

Thursday 15:00-16:30

IV-071Roberto Visintainer

stormTB: SimulaTOR of a murine Minimal-pbpk model for anti-TB drugs

Thursday 15:00-16:30

IV-072Alina Volkova

Mathematical modeling of autoimmune diseases: a systematic review and analysis for advancing therapeutic development

Thursday 15:00-16:30

IV-074Camille Vong

Multi-Endpoint Item-Response Modelling for Integrating Several Endpoints in Alzheimer’s Disease Drug Trials

Thursday 15:00-16:30

IV-077My Luong Vuong

Multiple imputation to handle missing covariate data in pharmacometrics modelling

Thursday 15:00-16:30

IV-081Sebastian Weber

Novel integrated population PD modeling framework to inform decision making during Oncology phase I dose-escalation

Thursday 15:00-16:30

IV-086Marie Wijk

A pragmatic approach to handling data below the lower limit of quantification in complex pharmacokinetic models

Thursday 15:00-16:30

IV-113Manuela Zimmermann

NLME modelling from a causal inference perspective when the dose-exposure-response relationship is confounded by the treatment regimen

Thursday 15:00-16:30

IV-116Laura Zwep

Statistical interaction modeling in non-linear mixed effect models: a case study in neonatal pharmacology

Thursday 15:00-16:30